Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
|Articles|April 28, 2015
Practical Management of Adverse Events Associated With Afatinib
In this video from the 2015 ONS meeting, Dr. Sipples talks about effective management of side effects for patients taking afatinib, an oral, targeted agent for lung cancer.
Advertisement
In this video from the 2015 ONS meeting, Dr. Sipples talks about effective management of side effects for patients taking afatinib, an oral, targeted agent for lung cancer.
Advertisement
Related to this article
SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.
The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5